A Phase 3, Randomized, Open Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R CHOP Compared to R CHOP in subjects with Newly Diagnosed Diffuse Large B Cell Lymphoma DLBCL EPCORE DLBCL2

About this Study

The primary objective of this study is to evaluate whether the addition of epcoritamab to 6 cycles of standard R CHOP followed by 2 cycles of epcoritamab can prolong progression free survival (PFS) compared with 6 cycles of standard R CHOP alone followed by 2 cycles of rituximab in subjects with newly diagnosed DLBCL with an IPI of 3 to 5.

Sponsor Protocol ID:M20-621
IRB Number:UMMC-IRB-2024-26
Actively Enrolling
Phase 3
March 25, 2024
Eligibility Criteria
Both Male and Female
Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Stephanie Elkins
How to participate in our Clinical Trials